• The total number of prevalent cases of primary prevention dyslipidemia in the countries under study will increase by 13%, from 67 million in 2016 to 76 million in 2026.
  • The total number of prevalent cases of secondary prevention dyslipidemia in the countries under study will increase by 25%, from 17.5 million in 2016 to 22 million in 2026.
  • Elevated LDL-cholesterol is the most common form of dyslipidemia among non-drug-treated persons in the countries under study.

Table of contents

  • Dyslipidemia - Epidemiology - Americas Data

Author(s): Ema Rodrigues, DSc, MPH

Ema is an epidemiologist with expertise in forecasting incident and prevalent populations within oncology, as well as some cardiovascular indications such as venous thromboembolism. She has significant experience with statistical methods such as multivariate linear regression, conditional logistic regression, principal components analysis, mixed models, hierarchical modeling, and path analysis to account for the complex relationships among various predictors of health outcomes, particularly correlated variables.

She completed her master’s and doctoral degree (MPH, D.Sc.) in Environmental Health at Boston University School of Public Health, where she worked on projects investigating significant predictors of various health outcomes including central nervous system cancer, cognitive function, and birth outcomes.

             


Related Reports

Dyslipidemia - Landscape & Forecast - Disease Landscape & Forecast

Dyslipidemia is a key modifiable risk factor for cardiovascular disease (CVD). Current lipid-modifying therapies, including statins, ezetimibe, fibrates,...

View Details

Dyslipidemia - Current Treatment - Detailed, Expanded Analysis: Physician Insights (US) : Hypertriglyceridemia

Hypertriglyceridemia refers to abnormalities in the concentration of triglycerides in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease and, with very high levels,...

View Details